Arcutis Biotherapeutics Inc
ARQT17.380USD
-0.330-1.86%
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
2.08BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Arcutis Biotherapeutics Inc Unternehmen
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.
Unternehmensinformationen
BörsenkürzelARQT
Name des UnternehmensArcutis Biotherapeutics Inc
IPO-datumJan 31, 2020
CEOMr. Todd Franklin Watanabe
Anzahl der mitarbeiter342
WertpapierartOrdinary Share
GeschäftsjahresendeJan 31
Addresse3027 Townsgate Road
StadtWESTLAKE VILLAGE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl91361
Telefon18054185006
Websitehttps://arcutis.com/
BörsenkürzelARQT
IPO-datumJan 31, 2020
CEOMr. Todd Franklin Watanabe
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+0.84%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
699.65K
-1.43%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
100.21K
--
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
65.02K
-0.14%
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Chairman of the Board
Independent Chairman of the Board
42.51K
+60.82%
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
35.80K
-50.23%
Ms. Sue-Jean Lin
Ms. Sue-Jean Lin
Independent Director
Independent Director
26.73K
+39.78%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Independent Director
Independent Director
23.36K
+48.32%
Ms. Terrie J. Curran
Ms. Terrie J. Curran
Independent Director
Independent Director
--
--
Ms. Halley E. Gilbert, J.D.
Ms. Halley E. Gilbert, J.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+0.84%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
699.65K
-1.43%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
100.21K
--
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
65.02K
-0.14%
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Chairman of the Board
Independent Chairman of the Board
42.51K
+60.82%
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
35.80K
-50.23%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Aug 15
Aktualisiert: Fri, Aug 15
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Suvretta Capital Management, LLC
9.62%
Jennison Associates LLC
9.27%
Rubric Capital Management LP
8.96%
Frazier Life Sciences Management, L.P.
8.24%
BlackRock Institutional Trust Company, N.A.
6.35%
Andere
57.57%
Aktionäre
Aktionäre
Anteil
Suvretta Capital Management, LLC
9.62%
Jennison Associates LLC
9.27%
Rubric Capital Management LP
8.96%
Frazier Life Sciences Management, L.P.
8.24%
BlackRock Institutional Trust Company, N.A.
6.35%
Andere
57.57%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
31.48%
Investment Advisor
31.34%
Hedge Fund
30.46%
Private Equity
8.24%
Research Firm
5.91%
Individual Investor
2.14%
Venture Capital
1.80%
Bank and Trust
0.42%
Pension Fund
0.28%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
481
131.17M
109.40%
-22.25M
2025Q1
487
132.87M
111.51%
-24.00M
2024Q4
453
136.04M
114.96%
-23.73M
2024Q3
433
136.12M
116.66%
-19.10M
2024Q2
416
134.94M
116.78%
-20.37M
2024Q1
392
131.83M
115.81%
+2.26M
2023Q4
366
104.30M
108.66%
+5.22M
2023Q3
364
79.57M
131.78%
-15.32M
2023Q2
359
84.02M
139.44%
-6.66M
2023Q1
352
83.59M
140.11%
+3.40M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Suvretta Capital Management, LLC
11.42M
9.58%
+23.84K
+0.21%
Mar 31, 2025
Jennison Associates LLC
11.36M
9.53%
-978.92K
-7.93%
Mar 31, 2025
Rubric Capital Management LP
10.97M
9.2%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
8.79M
7.37%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.91M
6.63%
-197.41K
-2.44%
Mar 31, 2025
The Vanguard Group, Inc.
6.79M
5.7%
+373.66K
+5.82%
Mar 31, 2025
Polar Capital LLP
6.71M
5.63%
-670.91K
-9.09%
Mar 31, 2025
State Street Global Advisors (US)
4.47M
3.75%
-476.52K
-9.63%
Mar 31, 2025
Gilder Gagnon Howe & Co. LLC
4.10M
3.44%
+193.06K
+4.95%
Mar 31, 2025
Morgan Stanley & Co. LLC
3.08M
2.58%
-403.45K
-11.59%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Sep 6
Aktualisiert: Sat, Sep 6
Name
Anteil
Simplify Health Care ETF
3.35%
SPDR S&P Biotech ETF
0.61%
Federated Hermes MDT Small Cap Core ETF
0.46%
First Trust Small Cap Growth AlphaDEX Fund
0.42%
Direxion Daily S&P Biotech Bull 3X Shares
0.35%
Invesco Nasdaq Biotechnology ETF
0.2%
ProShares Ultra Nasdaq Biotechnology
0.19%
iShares Biotechnology ETF
0.16%
First Trust Small Cap Core Alphadex Fund
0.14%
Vanguard US Momentum Factor ETF
0.12%
Mehr Anzeigen
Simplify Health Care ETF
Anteil3.35%
SPDR S&P Biotech ETF
Anteil0.61%
Federated Hermes MDT Small Cap Core ETF
Anteil0.46%
First Trust Small Cap Growth AlphaDEX Fund
Anteil0.42%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.35%
Invesco Nasdaq Biotechnology ETF
Anteil0.2%
ProShares Ultra Nasdaq Biotechnology
Anteil0.19%
iShares Biotechnology ETF
Anteil0.16%
First Trust Small Cap Core Alphadex Fund
Anteil0.14%
Vanguard US Momentum Factor ETF
Anteil0.12%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
